View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 30, 2011

Basilea Reports Positive Results of BAL30072

Basilea Pharmaceutica has reported positive top-line results from the Phase I study of its antibiotic BAL30072, used for the treatment of infections caused by multi-drug resistant Gram-negative bacteria. The double-blind randomised clinical Phase I study demonstrated the safety, tolera

By cms admin

Basilea Pharmaceutica has reported positive top-line results from the Phase I study of its antibiotic BAL30072, used for the treatment of infections caused by multi-drug resistant Gram-negative bacteria.

The double-blind randomised clinical Phase I study demonstrated the safety, tolerability and pharmacokinetics of BAL30072 at all dose levels.

Basilea Pharmaceutica CEO Anthony Man said the results support the potential of BAL30072 as a new treatment option for severe and life-threatening infections caused by multi-drug resistant Gram-negative bacteria.

“We will be further advancing the phase I programme with this promising drug this year,” Man said.

BAL30072 is a siderophore, an iron-binding sulfactam antibiotic.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU